Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer

Journal article

Peer reviewed

F. Raspagliesi, C. Lhommé, B.J. Monk, R.L. Coleman, T.J. Herzog, L. Navale, D.J. Warner and K. Fujiwara

Gynecologic oncology, Vol.133, pp.57-57

06/2014

Metrics

1 Record Views

Title: Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer
Creators: F. Raspagliesi - Fondazione IRCCS Istituto Nazionale dei Tumori
C. Lhommé - Institut Gustave Roussy
B.J. Monk - University of Arizona
R.L. Coleman - The University of Texas MD Anderson Cancer Center
T.J. Herzog - Columbia University
L. Navale - Amgen
D.J. Warner - The Thousand
K. Fujiwara - Saitama Medical University
Publication Details: Gynecologic oncology, Vol.133, pp.57-57
Publisher: Elsevier Inc
Identifiers: 991005969168102656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article